Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21

International Journal of Cancer

Volumn 85, Issue 5, 2000, Pages 659-666

  Ragupathi, Govindaswami ^a   Meyers, Michael ^a,b   Adluri, Sucharita ^a   Howard, Lisa ^a   Musselli, Cristina ^a   Livingston, Philip O ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GANGLIOSIDE GD3; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LACTONE; QS 21;

ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE ADHERENCE; IMMUNIZATION; MELANOMA; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODY FORMATION; AUTOANTIBODIES; CANCER VACCINES; CARBOHYDRATE SEQUENCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GANGLIOSIDES; HUMANS; IMMUNOGLOBULIN M; MELANOMA; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; SAPONINS; TIME FACTORS; VACCINES, CONJUGATE;

EID: 0033950463     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000301)85:5<659::AID-IJC11>3.0.CO;2-5     Document Type: Article

References (28)

1. 2 and its lactones. Markers for gliomas and neuroblastomas. Cancer Immunol. Immunother., 29, 171-178 (1989).
2. 3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo. Cancer Res., 48, 5680-5685 (1988).
3. HAMILTON, W.B., HELLING, F., LLOYD, K.O. and LIVINGSTON, P.O., Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int. J. Cancer, 53, 566-573 (1993).
4. HELLING, F., SHANG, A., CALVES, M., ZHANG, S., REN, S., YU, R.K., OETTGEN, H.F. and LIVINGSTON, P.O., GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res., 54, 197-203 (1994).
5. HELLING, F., ZHANG, S., SHANG, A., ADLURI, S., CALVES, M., KOGANTY, R., LONGENECKER, B.M., YAO, T.J., OETTGEN, H.F. and LIVINGSTON, P.O., GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res., 55, 2783-2788 (1995).
6. JURCIC, J.G., SCHEINBERG, D.A. and HOUGHTON, A.N., Monoclonal antibody therapy of cancer. In H.M. Pinedo, D.L. Longo and B.A. Chabner (eds.), Cancer chemotherapy and biological response modifiers annual 17, pp. 195-216, Elsevier, Amsterdam (1997).
7. KAWASHIMA, I., KOTANI, M., OZAWA, H., SUZUKI, M. and TAI, T., Generation of monoclonal antibodies specific for ganglioside lactones: evidence of the expression of lactone on human melanoma cells. Int. J. Cancer, 58, 263-268 (1994).
8. KAWASHIMA, I., OZAWA, H., KOTANI, M., SUZUKI, M., KAWANO, T., GOMIBUCHI, M. and TAI, T., Characterization of ganglioside expression in human melanoma cells: immunological and biochemical analysis. J. Biochem., 114, 186-193 (1993).
9. KENSIL, C.R., PATEL, U., LENNICK, M. and MARCIANI, D., Separation and characterization of saponins with adjuvant activity from Quillaja saponaria, Molina cortex. J. Immunol., 146, 431-437 (1991).
10. LIVINGSTON, P.O., Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol. Rev., 145, 147-166 (1995).
11. LIVINGSTON, P.O., ADLURI, S., HELLING, F., YAO, T.-J., KENSIL, C.R., NEWMAN, M.J. and MARCIANI, D., Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine, 12, 1275-1280 (1994).
12. LIVINGSTON, P.O., WATANABE, T., SHIKU, H., HOUGHTON, A.N., ALBINO, A., TAKAHASHI, T., RESNICK, L.A., MICHITSCH, R., PINSKY, C.M., OETTGEN, H.F. and OLD, L.J., Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells. Int. J. Cancer, 30, 413-422 (1982).
13. NORES, G.A., DOHI, T., TANIGUCHI, M. and HAKOMORI, S., Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. J. Immunol., 139, 3171-3176 (1987).
14. PORTOUKALIAN, J., CARREL, S., DORÉ, J.-F. and RÜMKE, P., Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides. Int. J. Cancer, 49, 893-899 (1991).
15. PUKEL, C.S., LLOYD, K.O., TRAVASSOS, L.R., DIPPOLD, W.G., OETTGEN, H.F. and OLD, L.J., GD3, A PROMINENT GANGLIOSIDE OF HUMAN MELANOMA. Detection and characterization by a mouse monoclonal antibody. J. exp. Med., 155, 1133-1147 (1982).
16. RAGUPATHI, G., Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol. Immunother., 43, 152-157 (1996).
17. RAGUPATHI, G., KOGANTY, R.R., QIU, D.X., LLOYD, K.O. and LIVINGSTON, P.O., A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconjugate J., 15, 217-221 (1998).
18. RAVINDRANATH, M.H., MORTON, D.L. and IRIE, R.F., An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res., 49, 3891-3897 (1989).
19. RAVINDRANATH, M.H., PAULSON, J.C. and IRIE, R.F., Human melanoma antigen O-acetylated ganglioside GD3 is recognized by Cancer antennarius lectin. J. biol. Chem., 263, 2079-2086 (1988).
20. RITTER, G., BOOSFELD, E., ADLURI, R., CALVES, M., OETTGEN, H.F., OLD, L.J. and LIVINGSTON, P., Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma. Int. J. Cancer, 48, 379-385 (1991).
21. RITTER, G., BOOSFELD, E., CALVES, M.J., OETTGEN, H.F., OLD, L.J. and LIVINGSTON, P.O., Antibody response to immunization with purified GD3 ganglioside and GD3 derivatives (lactones, amide and gangliosidol) in the mouse. Immunobiology, 182, 32-43 (1990a).
22. RITTER, G., BOOSFELD, E., MARKSTEIN, E., YU, R.K., REN, S.L., STALLCUP, W.B., OETTGEN, H.F., OLD, L.J. and LIVINGSTON, P.O., Biochemical and serological characteristics of natural 9-O-acetyl GD3 from human melanoma and bovine buttermilk and chemically O-acetylated GD3. Cancer Res., 50, 1403-1410 (1990b).
23. SCHEINBERG, D.A. and CHAPMAN, P.B., Therapeutic applications of monoclonal antibodies for human disease. In: J.R. Birch and E.S. Lennox (eds.), Monoclonal antibodies. Principles and applications, pp. 45-105, John Wiley & Sons, New York (1995).
24. SHIKU, H., TAKAHASHI, T., OETTGEN, H.F. and OLD, L.J., Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new cell surface antigens. J. exp. Med., 144, 873-881 (1976).
25. SVENNERHOLM, L., Chromatographic separation of human brain gangliosides. J. Neurochem., 10, 613-623 (1963).
26. TAI, T., KAWASHIMA, I., TADA, N. and IKEGAMI, S., Different reactivities of monoclonal antibodies to ganglioside lactones. Biochim. biophys. Acta, 958, 134-138 (1988).
27. YAMAGUCHI, H., FURUKAWA, K., FORTUNATO, S.R., LIVINGSTON, P.O., LLOYD, K.O., OETTGEN, H.F. and OLD, L.J., Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc. nat. Acad. Sci. (Wash.), 84, 2416-2420 (1987).
28. ZHANG, S., HELLING, F., LLOYD, K.O. and LIVINGSTON, P.O., Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides. Cancer Immunol. Immunother., 40, 88-94 (1995).